{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IDH+Mutation&page=2", "query": { "condition": "IDH Mutation", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IDH+Mutation&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T18:37:26.008Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03434262", "title": "SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Ependymoma", "Anaplastic Ganglioglioma", "Anaplastic Meningioma", "Anaplastic Oligodendroglioma", "Pleomorphic Xanthoastrocytoma, Anaplastic", "Atypical Teratoid/Rhabdoid Tumor", "Brain Cancer", "Brain Tumor", "Central Nervous System Neoplasms", "Choroid Plexus Carcinoma", "CNS Embryonal Tumor With Rhabdoid Features", "Ganglioneuroblastoma of Central Nervous System", "CNS Tumor", "Embryonal Tumor of CNS", "Ependymoma", "Glioblastoma", "Glioma", "Glioma, Malignant", "Medulloblastoma", "Medulloblastoma; Unspecified Site", "Medulloepithelioma", "Neuroepithelial Tumor", "Neoplasms", "Neoplasms, Neuroepithelial", "Papillary Tumor of the Pineal Region (High-grade Only)", "Pediatric Brain Tumor", "Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only)", "Pineoblastoma", "Primitive Neuroectodermal Tumor", "Recurrent Medulloblastoma", "Refractory Brain Tumor", "Neuroblastoma. CNS", "Glioblastoma, IDH-mutant", "Glioblastoma, IDH-wildtype", "Medulloblastoma, Group 3", "Medulloblastoma, Group 4", "Glioma, High Grade", "Neuroepithelial Tumor, High Grade", "Medulloblastoma, SHH-activated and TP53 Mutant", "Medulloblastoma, SHH-activated and TP53 Wildtype", "Medulloblastoma, Chromosome 9q Loss", "Medulloblastoma, Non-WNT Non-SHH, NOS", "Medulloblastoma, Non-WNT/Non-SHH", "Medulloblastoma, PTCH1 Mutation", "Medulloblastoma, WNT-activated", "Ependymoma, Recurrent", "Glioma, Recurrent High Grade", "Glioma, Recurrent Malignant", "Embryonal Tumor, NOS", "Glioma, Diffuse Midline, H3K27M-mutant", "Embryonal Tumor With Multilayered Rosettes (ETMR)", "Ependymoma, NOS, WHO Grade III", "Ependymoma, NOS, WHO Grade II", "Medulloblastoma, G3/G4", "Ependymoma, RELA Fusion Positive" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "ribociclib", "type": "DRUG" }, { "name": "sonidegib", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "39 Years", "sex": "ALL", "summary": "1 Year to 39 Years" }, "enrollment_count": 68, "start_date": "2018-03-05", "completion_date": "2024-05-24", "has_results": false, "last_update_posted_date": "2024-05-31", "last_synced_at": "2026-06-25T18:37:26.008Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03434262" }, { "nct_id": "NCT06478212", "title": "Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "IDH1-mutant Glioma", "IDH2-mutant Glioma" ], "interventions": [ { "name": "Vorasidenib", "type": "DRUG" }, { "name": "Temozolomide (TMZ)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 51, "start_date": "2025-01-22", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-25T18:37:26.008Z", "location_count": 6, "location_summary": "Los Angeles, California • Miami, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06478212" }, { "nct_id": "NCT04762602", "title": "A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Isocitrate Dehydrogenase Gene Mutation" ], "interventions": [ { "name": "HMPL-306", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchmed", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2021-02-28", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-06-25T18:37:26.008Z", "location_count": 8, "location_summary": "Santa Monica, California • Atlanta, Georgia • Iowa City, Iowa + 4 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04762602" }, { "nct_id": "NCT03528642", "title": "Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Astrocytoma, IDH-Mutant, Grade 2", "Astrocytoma, IDH-Mutant, Grade 3" ], "interventions": [ { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Telaglenastat Hydrochloride", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "OTHER", "RADIATION", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 40, "start_date": "2019-05-01", "completion_date": "2026-09-11", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-06-25T18:37:26.008Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03528642" }, { "nct_id": "NCT02273739", "title": "Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Glioma", "Angioimmunoblastic T-cell Lymphoma", "Intrahepatic Cholangiocarcinoma", "Chondrosarcoma" ], "interventions": [ { "name": "Enasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2014-12-08", "completion_date": "2016-06-03", "has_results": true, "last_update_posted_date": "2021-02-23", "last_synced_at": "2026-06-25T18:37:26.008Z", "location_count": 10, "location_summary": "Los Angeles, California • Miami, Florida • Baltimore, Maryland + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02273739" }, { "nct_id": "NCT06666712", "title": "Chronic CED of TPT for Recurrent Malignant Glioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Tumor, Recurrent", "Malignant Glioma (WHO Grade III or IV)", "IDH1/IDH2 Mutation" ], "interventions": [ { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jeffrey N. Bruce", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2026-06-12", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-06-25T18:37:26.008Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06666712" }, { "nct_id": "NCT04955938", "title": "A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "IDH Mutation", "IDH1 Mutation", "IDH2 Gene Mutation", "Blood Cancer", "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Ivosidenib", "type": "DRUG" }, { "name": "Enasidenib", "type": "DRUG" }, { "name": "Fedratinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-10-29", "completion_date": "2023-06-07", "has_results": false, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-06-25T18:37:26.008Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04955938" }, { "nct_id": "NCT02719574", "title": "Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Myelogenous Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "FT-2102 (olutasidenib)", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forma Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 336, "start_date": "2016-04-30", "completion_date": "2024-01-24", "has_results": true, "last_update_posted_date": "2025-06-26", "last_synced_at": "2026-06-25T18:37:26.008Z", "location_count": 19, "location_summary": "Los Angeles, California • Sacramento, California • New Haven, Connecticut + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02719574" }, { "nct_id": "NCT05406700", "title": "Niraparib In Recurrent IDH 1/2 Gliomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Low-grade Glioma", "IDH2 Gene Mutation", "Recurrent Glioma", "IDH1 Mutation", "Glioma, Malignant" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Resection/Treatment with Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2023-05-18", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-06-25T18:37:26.008Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05406700" }, { "nct_id": "NCT03953898", "title": "Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Acute Myeloid Leukemia Post Cytotoxic Therapy", "Recurrent Acute Myeloid Leukemia", "Recurrent Myelodysplastic Syndrome", "Refractory Acute Myeloid Leukemia", "Refractory Myelodysplastic Syndrome" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2020-08-04", "completion_date": "2027-03-04", "has_results": true, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-25T18:37:26.008Z", "location_count": 11, "location_summary": "Orange, California • New Haven, Connecticut • Coral Gables, Florida + 8 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03953898" } ] }